CAR T-cell Therapy | Specialty

The OncLive CAR T-cell therapy condition center page is a comprehensive resource for clinical news and expert insights on FDA-approved and investigational CAR T-cell products in hematologic malignancies, specifically acute lymphoblastic leukemia, non-Hodgkin lymphoma, and multiple myeloma. CAR T-cell research in solid tumors is also under exploration. This page features news articles, interviews in written and video format, and podcasts that focus on updates with CAR T-cell therapy and the ongoing research with this type of treatment.

Dr Frank on the Background of Investigating CAR22 Therapy in Relapsed/Refractory LBCL

August 31st 2023

Matthew Frank, MD, PhD, discusses findings from prior research investigating a CD22-directed CAR T-cell therapy that informed the rationale for launching a phase 1 trial with this agent in patients with relapsed/refractory large B-cell lymphoma.

CAR T-Cell Therapy Innovations Unfold Across the Spectrum of Cancer Care

August 31st 2023

Martin E. Gutierrez, MD, and Lori A. Leslie, MD, discuss common barriers to implementing CAR T-cell therapy programs, early successes that John Theurer Cancer Center in New Jersey has seen with outpatient CAR T-cell therapy administration, and developments on the horizon for administering this approach in solid tumors

Dr Kambhampati on the Rationale For Evaluating Real-World Outcomes With Brexu-Cel in MCL

August 30th 2023

Swetha Kambhampati, MD, discusses the rationale for evaluating outcomes with in a subgroup anlaysis of patients with relapsed/refractory mantle cell lymphoma, and how prior data from the phase 3 ZUMA-2 study supported the inception of this trial.

Dr Kambhampati on the Potential Use of Brexu-Cel in Earlier Treatment Lines in MCL

August 29th 2023

Swetha Kambhampati, MD, discusses how findings from a subgroup analysis of investigating the use of brexucabtagene autoleucel in relapsed/refractory mantle cell lymphoma may support the continued exploration of this agent in earlier lines of therapy.

FDA Awards Orphan Drug Designation to NXC-201 for Multiple Myeloma

August 23rd 2023

The FDA has granted orphan drug designation to NXC-201 for use as a potential therapeutic option in patients with multiple myeloma.

Second-Line Axi-Cel Elicits Complete Metabolic Responses in Transplant-Ineligible LBCL

August 18th 2023

Second-line treatment with axicabtagene ciloleucel led to an investigator-assessed, 3-month complete metabolic response rate of 71.0% in patients with large B-cell lymphoma who were ineligible for autologous stem cell transplant.

Evolving Drug Classes Expand Treatment Options Across Hematologic Malignancies

August 18th 2023

Individualized myelofibrosis treatment begins with correctly identifying a patient’s disease subtype and considering their symptoms, from which accurate decisions regarding the use of JAK inhibitors vs radiation vs hypomethylating agents can lead to spleen and symptom burden reductions.

MB-106 Shows Continued Activity in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

August 16th 2023

MB-106, a first-in-class, CD20-targeted autologous CAR T-cell therapy, led to durable clinical responses with low-grade cytokine release syndrome in patients with indolent lymphoma.

FDA Lifts Clinical Hold on BCMA-Directed Modified CAR T-Cell Therapy in Multiple Myeloma

August 15th 2023

The FDA has lifted the partial clinical hold placed on the clinical program evaluating the investigational new drug, CART-ddBCMA, in the treatment of patients with relapsed/refractory multiple myeloma.

Dr Frank on Sequencing Questions With CAR22 in Relapsed/Refractory LBCL

August 4th 2023

Matthew J. Frank, MD, PhD, discusses remaining questions regarding treatment sequencing following preliminary results from a phase 1 trial of a CD22-directed CAR-T therapy in relapsed/refractory large B-cell lymphoma.

CD22-Targeted CAR T Cells Elicit Responses With Acceptable Safety in Heavily Pretreated LBCL

August 3rd 2023

Matthew Frank, MD, PhD, discusses the rationale for evaluating CD22 CAR T cells in heavily pretreated patients with large B-cell lymphoma, important safety and efficacy data with this approach, next steps for this research, and how continued efforts may shed needed light on sequencing in this space.

Real-World Outcomes With Brexu-Cel Are Consistent With Clinical Data in R/R MCL, Regardless of Prior Treatment

August 2nd 2023

Swetha Kambhampati, MD, explains the need for real-world data on responses to brexu-cel in patients with relapsed/refractory MCL, compares safety and efficacy data from the subgroup analysis with prior results from ZUMA-2, and discusses how these findings support more long-term follow-up in this population.

NKX019 Showcases Manageable Safety, Early Activity in R/R B-cell Non-Hodgkin Lymphoma

July 27th 2023

The allogeneic natural killer cell therapy NKX019 was found to have an acceptable toxicity profile and to induce deep and durable responses in patients with relapsed or refractory B-cell non-Hodgkin lymphomas.

Dr Matous on the Future Directions of CAR T-Cell Therapy in Multiple Myeloma

July 25th 2023

Jeffrey V. Matous, MD, discusses future directions of CAR T-cell therapy in multiple myeloma, highlighting the potential promise of novel targets beyond BCMA.

CB-010 Elicits 94% ORR in Relapsed/Refractory Non-Hodgkin Lymphoma

July 18th 2023

The allogeneic CAR T-cell therapy CB-010 demonstrated early signs of durable antitumor activity and favorable safety in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.

Dr Matous on Barriers to CAR T-Cell Therapy Administration in Multiple Myeloma

July 13th 2023

Jeffrey V. Matous, MD, discusses potential strategies to overcome barriers to receiving CAR T-cell therapy for patients with multiple myeloma, and how the potential use of these agents in earlier lines could improve infusion wait times and rates of disease progression.

huCART19-IL8 Proves Safe and Elicits Durable Responses in CAR T–Pretreated R/R Lymphoma

July 3rd 2023

huCART19-IL8 had acceptable safety and induced durable responses in patients with lymphoma who were refractory or relapsed following second-generation CD19-targeted CAR T-cell therapies, according to data from a first-in-human phase 1 trial.

Dr Sasine on the Potential Use of Cilta-Cel in Earlier Lines for Multiple Myeloma

June 30th 2023

Joshua P. Sasine, MD, PhD, discusses the potential role of cilta-cel in earlier lines of therapy for patients with multiple myeloma.

Current Treatment Perspectives for CAR T-Cell Therapy in R/R B-Cell Lymphoma

June 28th 2023

Chimeric antigen receptor T-cell therapy has proven to be an effective adoptive cellular therapy against relapsed/refractory B-cell lymphoma.

NKX101 Demonstrates Early Activity in Relapsed/Refractory AML

June 27th 2023

Treatment with NKX101 led to a best composite complete response rate of 67% in patients with relapsed/refractory acute myeloid leukemia, according to updated data from a dose-expansion cohort of an ongoing phase 1 trial.